U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H14O6S2
Molecular Weight 246.302
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUSULFAN

SMILES

CS(=O)(=O)OCCCCOS(C)(=O)=O

InChI

InChIKey=COVZYZSDYWQREU-UHFFFAOYSA-N
InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB01008 https://en.wikipedia.org/wiki/Busulfan

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic). Most common adverse reactions (incidence greater than 60%) were: myelosuppression, nausea, stomatitis, vomiting, anorexia, diarrhea, insomnia, fever, hypomagnesemia, abdominal pain, anxiety, headache, hyperglycemia and hypokalemia. Itraconazole and acetaminophen can decrease busulfan clearance. Phenytoin increases hepatic clearance of busulfan.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Busulfan is a small, highly lipophilic molecule that easily crosses the blood brain barrier.

Originator

Chester Beatty Research Institute
1
Sources: Lichtman M., 'Hematology: Landmark Papers of the Twentieth Century' (2000), P. 598. ISBN-13 | 978-0124485105

Approval Year

1954
119
Targets

Targets

Primary TargetPharmacologyConditionPotency
Crosslinking Agent
83
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
MYLERAN

Approved Use

BUSULFEX is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. BUSULFEX is an alkylating drug indicated for: •Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) (1)

Launch Date

1954
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1222 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1167 μM × min
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.35 h
OTHER GOV
https://www.ema.europa.eu/en/documents/product-information/busilvex-epar-product-information_en.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
67.6%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
40 mg/m2 4 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 4 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
unhealthy, 1.2–17.2
Health Status: unhealthy
Age Group: 1.2–17.2
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Disc. AE: Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
4 mg/kg 4 times / day multiple, oral
Overdose
Dose: 4 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Disc. AE: Seizures...
AEs leading to
discontinuation/dose reduction:
Seizures
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
18 mg/kg single, oral
Overdose
Dose: 18 mg/kg
Route: oral
Route: single
Dose: 18 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
unhealthy, 48
Health Status: unhealthy
Age Group: 48
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Disc. AE: Myelosuppression, Seizures...
AEs leading to
discontinuation/dose reduction:
Myelosuppression (severe)
Seizures
Venoocclusive disease
Fetal damage
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Hepatotoxicity Disc. AE
40 mg/m2 4 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 4 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
unhealthy, 1.2–17.2
Health Status: unhealthy
Age Group: 1.2–17.2
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Seizures Disc. AE
4 mg/kg 4 times / day multiple, oral
Overdose
Dose: 4 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Fetal damage Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Seizures Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Venoocclusive disease Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Myelosuppression severe
Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2A6
879

CYP2C19
2057

CYP2E1
1060

BSEP
550

OATP1B1
1079

OATP1B3
961

MRP2
499

MRP3
246

MRP4
290
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no [IC50 >10 uM]
CYP2A6
911
 no [IC50 >10 uM]
CYP2C19
2141
 no [IC50 >10 uM]
CYP2C9
2497
 no [IC50 >10 uM]
CYP2D6
2546
 no [IC50 >10 uM]
CYP2E1
1146
 no [IC50 >10 uM]
BSEP
554
 no [IC50 >1000 uM]
MRP2
625
 no [IC50 >133 uM]
MRP3
326
 no [IC50 >133 uM]
MRP4
345
 no [IC50 >133 uM]
CYP3A4
2633
 no [IC50 >812 uM]
OATP1B1
1095
 yes
OATP1B3
970
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:28901
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28901
ChemicalBook
CB2105891
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2105891
ChemicalBook
CB72673681
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72673681
eMolecules
486878
https://www.emolecules.com/cgi-bin/more?vid=486878
MolPort
MolPort-001-783-406
https://www.molport.com/shop/molecule-link/MolPort-001-783-406
Selleck Chemicals
Busulfan(Busulfex)
http://www.selleckchem.com/products/Busulfan(Busulfex).html
ZINC
ZINC000001530572
http://zinc15.docking.org/substances/ZINC000001530572
PubMed

PubMed

TitleDatePubMed
Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies.
2001-10-15
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
2001-10
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
2001-10
Monitoring of busulfan area under the curve: estimation by a single measurement.
2001-10
New method for thyroid transplantation across major histocompatibility complex barriers using allogeneic bone marrow transplantation.
2001-09-27
Arsenic trioxide in the management of acute promyelocytic leukaemia.
2001-09-08
Sexual differentiation of germ cell deficient gonads in the medaka, Oryzias latipes.
2001-09-01
[Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
2001-09
Allogeneic bone marrow transplantation-mediated transfer of specific immunity against Toxocara canis associated with excessive IgE.
2001-09
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
2001-09
Unexplained pulmonary hypertension in chronic myeloproliferative disorders.
2001-09
Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
2001-09
Neonatal bone marrow transplantation for severe combined immunodeficiency.
2001-09
Developing a pediatric outpatient transplantation program. The Children's Memorial Hospital experience.
2001-08-01
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.
2001-08-01
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
2001-08-01
[Successful second transplant from one-locus HLA-mismatched unrelated donor for graft rejection following initial transplant from another unrelated donor in a patient with chronic myelogenous leukemia].
2001-08
Griscelli syndrome: report of the first peripheral blood stem cell transplant and the role of mutations in the RAB27A gene as an indication for BMT.
2001-08
Atypical retinal microvasculopathy after bone marrow transplantation.
2001-08
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
2001-08
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
2001-08
The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro.
2001-08
Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry.
2001-08
Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.
2001-08
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
2001-08
Overview of the treatment of infant central nervous system tumors: medulloblastoma as a model.
2001-07-24
No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission.
2001-07-15
Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.
2001-07-15
Autologous peripheral blood stem cell transplantation for patients with malignancies: the Tri-Service General Hospital experience.
2001-07
Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.
2001-07
Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant.
2001-07
High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
2001-07
Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning.
2001-07
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
2001-07
Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial.
2001-06-15
Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.
2001-06
A cautionary tale: how to delete mouse haemopoietic stem cells with busulphan.
2001-06
Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation.
2001-06
Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
2001-05
High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
2001-05
Hydroxyurea and periodicity in myeloproliferative disease.
2001-05
Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
2001-04
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
2001-04
Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
2001-04
Pharmacodynamics of high-dose chemotherapy.
2001-03
Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis.
2001-03
Systemic fusariosis after a preparative regimen including thiotepa, VP-16 and busulfan used for blood stem cell transplantation in Hodgkin's disease.
2001-01
A new method for tolerance induction: busulfan administration followed by intravenous injection of neuraminidase-treated donor bone marrow.
2001
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma.
2001
[Hemorrhagic cystitis related to the high-dose conditioning therapy in a bone marrow recipient].
2001
Patents

Patents

05994391
1
06107494
1
20010004454
41
JP2006502184A
41
JP2007525670A
150
JP2008533019A
34
JP2011525178A
25
JP2011528275A
456
JP2012500104A
108
JP4663232B2
15

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Oral administration: adult dose range for remission induction is 4 to 8 mg, total dose, daily. Dosing on a weight basis is the same for both pediatric patients and adults, approximately 60 mcg/kg of body weight or 1.8 mg/m2 of body surface, daily. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2
0.8 mg per kg intravenously six hours for four consecutive days for a total of 16 doses
Route of Administration: Intravenous
In Vitro Use Guide
P39 myeloid cells were incubated with busulfan in concentrations ranging from 10 to 100 microg/ml for 2, 4 or 8 h, then washed and cultured in busulfan-free medium for 72 h.
Name Type Language
BUSULFAN
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
1,4-BUTANEDIYL DIMETHANESULFONATE
Preferred Name English
BUSULFANUM [WHO-IP LATIN]
Common Name English
BUSULFAN [MI]
Common Name English
BUSULFAN [JAN]
Common Name English
BUSULFAN [EMA EPAR]
Common Name English
BUSILVEX
Brand Name English
BUSULFAN [USP MONOGRAPH]
Common Name English
BUSULFAN [MART.]
Common Name English
BUSULFAN [IARC]
Common Name English
BUSULFAN [VANDF]
Common Name English
1,4-BUTANEDIOL DIMETHANESULPHONATE
Systematic Name English
TETRAMETHYLENE DI(METHANESULFONATE)
Systematic Name English
BUSULFAN [HSDB]
Common Name English
LEUCOSULFAN
Common Name English
SULPHABUTIN
Common Name English
BUSULFAN [EP IMPURITY]
Common Name English
1,4-BUTANEDIOL, DIMETHANESULFONATE
Systematic Name English
Busulfan [WHO-DD]
Common Name English
1,4-Butanediol dimethanesulfonate
Systematic Name English
BUSULPHAN
Systematic Name English
BUSULFEX
Brand Name English
BUSULFAN FRESENIUS KABI
Brand Name English
NSC-750
Code English
NCI-C01592
Code English
BUSULFAN [ORANGE BOOK]
Common Name English
busulfan [INN]
Common Name English
MYELOSANUM [WHO-IP]
Common Name English
1,4-BUTANEDIOL, DIMETHANESULPHONATE
Systematic Name English
BUSULFAN [EP MONOGRAPH]
Common Name English
BUSULFAN [WHO-IP]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BUSULFAN FRESENIUS KABI (AUTHORIZED: HEMATOPOIETIC STEM CELL TRANSPLANTATION)
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 140700
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 394513
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
NDF-RT N0000000236
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 160402
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 81694
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
LIVERTOX NBK548886
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 161602
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
NDF-RT N0000175558
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
EU-Orphan Drug EU/3/00/011
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
WHO-VATC QL01AB01
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 105897
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
EMA ASSESSMENT REPORTS BUSILVEX (AUTHORIZED: HEMATOPOIETIC STEM CELL TRANSPLANTATION)
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 83094
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
WHO-ATC L01AB01
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
IARC Busulfan
NCI_THESAURUS C222
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
Code System Code Type Description
MESH
D002066
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
EVMPD
SUB05993MIG
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
ALANWOOD
busulfan
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
WIKIPEDIA
BUSULFAN
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
RXCUI
1828
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB01008
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
BUSULFAN
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY Description: A white, crystalline powder. Solubility: Very slightly soluble in water; sparingly soluble in acetone R; slightly soluble in ethanol (~750 g/l) TS. Category: Cytotoxic drug. Storage: Busulfan should be kept in a well-closed container, protected from light. Additional information: CAUTION: Busulfan must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Busulfan contains not less than 98.5% and not more than 100.5% of C6H14O6S2, calculated with reference to the dried substance.
CAS
55-98-1
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
SMS_ID
100000085245
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
IUPHAR
7136
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
DRUG CENTRAL
438
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
PUBCHEM
2478
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
NCI_THESAURUS
C321
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
HSDB
7605
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
FDA UNII
G1LN9045DK
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
LACTMED
Busulfan
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
DAILYMED
G1LN9045DK
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
CHEBI
28901
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
MERCK INDEX
m2778
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY Merck Index
NSC
750
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-250-2
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
INN
564
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
EPA CompTox
DTXSID3020910
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
ChEMBL
CHEMBL820
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of BUSULFAN
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966